Immune System Diseases

905 trials 381 recruiting

Filter these 905 trials by phase, country and sponsor.

Open in Search →

Phase II-III study to assess the efficacy and safety of sublingual immunotherapy in patients suffering from birch pollen allergy Ended

2023-505567-37-00 Moderate-to-severe allergic rhinitis / rhinoconjunctivi 10 2023-08-22
A Phase I (First-in-Human) Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and… Ended

2023-504450-35-00 Plaque psoriasis 1 2023-08-21
A multicentre, randomised, double-blind, placebo-controlled, 12-week parallel-group trial to evaluate the efficacy and safety of oral BP1.78… Ended

2022-502045-10-00 Atopic dermatitis 4 2023-08-11
The Italian Cohort (ITACO) and the Analytical Antiretroviral Treatment Interruption Italian Cohort (ITACO-ATI) study guided by molecular HIV… Ended

2024-518694-33-00 perinatally HIV infection 5 2023-08-08
A Phase 1/2, Open-Label, Multicenter Study of KYV-101, an Autologous Fully-Human Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) The… Ended

2024-513329-22-00 Lupus Nephritis 7 2023-07-20
A study investigating the absorption and food effect of different tablet formulations of JNJ-77242113, a new compound in the treatment of in… Ended

2023-504720-26-00 Inflammatory Conditions 3 2023-07-19
TRIAL EVALUATING EFFICACY AND SAFETY OF HYDROXYCHLOROQUINE VERSUS PLACEBO IN EARLY SYSTEMIC SCLEROSIS (SSc) Ended

2024-516050-22-00 Systemic Sclerosis (SSc) is a rare and orphan disease ( 5 2023-07-13
A Phase 3 Study Investigating the Efficacy, Safety, and Tolerability of Ritlecitinib in Participants with Nonsegmental Vitiligo Ended

2022-501668-16-00 NON SEGMENTAL VITILIGO 5 2023-06-26
A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (S… Ended

2022-501752-29-00 Hidradenitis Suppurativa 5 2023-06-15
Graves' disease is an immune system disorder that results in the overproduction of thyroid hormones. Ended

2024-512647-23-00 Grave's disease 4 2023-06-14
First-in-human study of SAR445611 in healthy adult participants Ended

2022-502923-23-00 Immune system diseases 1 2023-06-12
A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (S… Ended

2022-501753-36-00 Hidradenitis Suppurativa 5 2023-06-02
This is a study to evaluate dose-flexibility of Upadacitinib in Adult Subjects with Moderate to Severe Atopic Dermatitis Ended

2023-504869-23-00 Dermatitis atopic 11 2023-05-31
Study of M5049 in DM and PM Participants (NEPTUNIA) Ended

2022-501351-82-00 Dermatomyositis, Polymyositis 4 2023-05-23
A Phase 2 trial to evaluate the efficacy and safety of daxdilimab in participants with primary discoid lupus erythematosus. Ended

2023-509746-35-00 Primary Discoid Lupus Erythematosus 4 2023-05-16
A Phase 2 Proof of Concept Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of OMS90… Ended

2022-501190-39-01 Paroxysmal nocturnal hemoglobinuria 3 2023-05-15
Phase 3, 52-week Study Evaluating Rocatinlimab (AMG451)in Adolescent Subjects With Moderate-to-severe AD (ROCKET-ASTRO) Ended

2022-501586-50-00 Atopic Dermatitis 5 2023-05-15
Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab (AMG 451) in Combination with Topical Corticosteroids and/or Topical … Ended

2022-501585-22-00 Atopic Dermatitis 5 2023-05-11
A Phase 3 open-label, controlled, randomised, multi-centre trial comparing imlifidase and standard-of-care with standard-of-care alone in th… Ended

2022-500121-33-01 Anti-GBM antibody disease (Goodpasture disease) 5 2023-05-08
A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe AD (ROCKET-Horizon) Ended

2022-501538-44-00 Atopic Dermatitis 5 2023-04-25
A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab Monotherapy in Moderate-to-severe AD (ROCKET-Ignite) Ended

2022-501540-15-00 Atopic Dermatitis 5 2023-04-25
A Phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of intravenous efzofitimod in patients wit… Ended

2023-506039-13-00 pulmonary sarcoidosis 5 2023-04-12
A Study of Peresolimab (LY3462817) in Adults Participants With Moderately-to-Severely Active Rheumatoid Arthritis Ended

2022-501425-20-00 Rheumatoid Arthritis Arthritis Joint Diseases Muscul 4 2023-04-03
A Open-label Study to Evaluate the Efficacy, Safety, Tolerability of HZN-825 in Patients with Diffuse Cutaneous Systemic Sclerosis Ended

2023-509783-23-00 Diffuse Cutaneous Systemic Sclerosis 4 2023-02-24